Vigonvita Life Sciences Co., Ltd. filed its Monthly Return for Equity Issuer for the period ended 31 July 2026 with the Hong Kong Stock Exchange, detailing a substantial restructuring of its share classes.

Key transaction • On 15 July 2026, 100.22 million domestic unlisted ordinary shares were converted into an equal number of H shares. • The conversion left the company’s total issued share count unchanged but shifted the composition decisively toward the Hong Kong-listed class.

Authorised / registered share capital (par value: RMB 1) • H shares authorised rose from 66.68 million to 166.90 million. • Domestic unlisted shares authorised declined correspondingly to 0.70 million. • Overall authorised capital closed the month at 167.60 million shares.

Issued share structure after conversion • H shares in issue increased from 66.68 million to 166.90 million. • Domestic unlisted shares in issue dropped to 0.70 million. • No treasury shares were outstanding.

Public-float status The company confirmed compliance with the Main Board’s 25 % minimum public-float requirement for its H shares as at 31 July 2026.

Administrative confirmation The filing states that the share conversion was duly authorised by the board and executed in accordance with all applicable listing rules and regulatory requirements, with all proceeds received and statutory filings completed.